Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial

Yang,Wei; Zhou,Yu‑Jie; Fu,Yan; Qin,Jian; Tan,Shu; Chen,Xiao‑Min; Guo,Jin‑Cheng; Wang,De‑Zhao; Zhan,Hong; Guan,Wei; Xu,Ya‑Wei; He,Jing‑Yu; Li,Jing; Hua,Qi

doi:10.3892/etm.2016.3302

Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial

Authors:
- Wei Yang
- Yu‑Jie Zhou
- Yan Fu
- Jian Qin
- Shu Tan
- Xiao‑Min Chen
- Jin‑Cheng Guo
- De‑Zhao Wang
- Hong Zhan
- Wei Guan
- Ya‑Wei Xu
- Jing‑Yu He
- Jing Li
- Qi Hua
View Affiliations

Affiliations: Department of Geriatrics, Xuan Wu Hospital, Capital Medical University, Beijing 100053, P.R. China, Department of Cardiology, An Zhen Hospital Affiliated to Capital Medical University, Beijing 100029, P.R. China, Emergency Department, Tong Ren Hospital Affiliated to Capital Medical University, Beijing 100005, P.R. China, Department of Cardiology, Xuan Wu Hospital, Capital Medical University, Beijing 100053, P.R. China, Department of Cardiology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Cardiology, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China, Department of Cardiology, Luhe Hospital, Affiliated to Capital Medial University, Beijing 101100, P.R. China, Department of Cardiology, Mentougou District Hospital of Beijing City, Beijing 102300, P.R. China, Emergency Department, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Cardiology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150030, P.R. China, Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: April 27, 2016 https://doi.org/10.3892/etm.2016.3302
Pages: 115-122
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urapidil has been proposed to be an effective vasodilator for the treatment of acute decompensated heart failure (ADHF); however, its effect on cardiac function, as compared with that of nitroglycerin, in elderly patients with hypertension and ADHF has yet to be determined. In the present study, a multicenter, open‑label clinical trial was performed, in which 120 elderly patients with hypertension and ADHF were randomly assigned to the treatment (50‑400 µg/min intravenous urapidil) or control group (5‑40 µg/min intravenous nitroglycerin). The dosages of the medications were adjusted according to the blood pressure of the patients. The systolic and diastolic blood pressure, heart rate and serum level of N‑terminal pro B‑type natriuretic peptide (NT‑proBNP) were evaluated at hospital admission and at days 1, 2, 3 and 7 after treatment. In addition, the left ventricular function was assessed by measuring the left ventricular ejection fraction (LVEF) and left ventricular end‑diastolic volume at hospital admission and at days 2 and 7 after treatment. The results indicated that intravenous administration of urapidil and nitroglycerin were effective in lowering the blood pressure and heart rate within 7 days, with no significant differences observed between the two groups (P>0.05). By contrast, greater reduction in the serum NT‑proBNP level (2,410.4±546.1 vs. 4,234.1±876.4 pg/ml; P<0.05) and greater improvement in the LVEF (55.3±3.4 vs. 45.2±2.4%; P<0.05) were observed in the urapidil‑treated group, as compared with the nitroglycerin‑treated group. No adverse events were reported during the treatment period in the two groups. The clinical outcomes at 6 months following discharge were evaluated and were not found to be significantly different between the two groups. In conclusion, the present results of the present study suggested that urapidil was as effective as nitroglycerin in controlling blood pressure and heart rate and was more effective in improving cardiac systolic function in elderly patients with hypertension and ADHF.

View Figures

View References

1.	Jiang H and Ge J: Epidemiology and clinical management of cardiomyopathies and heart failure in China. Heart. 95:1727–1731. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology: Chinese guidelines for the diagnosis and treatment of heart failure 2014. Zhonghua Xin Xue Guan Bing Za Zhi. 42:98–122. 2014.(In Chinese). PubMed/NCBI
3.	Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, et al: American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation. 131:e29–322. 2015. View Article : Google Scholar : PubMed/NCBI
4.	Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH and Rodgers JE: Acute decompensated heart failure: Evolving literature and implications for future practice. Pharmacotherapy. 34:373–388. 2014. View Article : Google Scholar : PubMed/NCBI
5.	Felker GM, Adams KF Jr, Konstam MA, O'Connor CM and Gheorghiade M: The problem of decompensated heart failure: Nomenclature, classification and risk stratification. Am Heart J. 145(Suppl 2): S18–S25. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M and Horton DP: ADHERE Scientific Advisory Committee and Investigators: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 149:209–216. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Zannad F, Mebazaa A, Juillière Y, Cohen-Solal A, Guize L, Alla F, Rougé P, Blin P, Barlet MH, Paolozzi L, et al: Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail. 8:697–705. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Piper S and McDonagh T: The role of intravenous vasodilators in acute heart failure management. Eur J Heart Fail. 16:827–834. 2014. View Article : Google Scholar : PubMed/NCBI
9.	Levy PD, Laribi S and Mebazaa A: Vasodilators in acute heart failure: Review of the latest studies. Curr Emerg Hosp Med Rep. 2:126–132. 2014. View Article : Google Scholar : PubMed/NCBI
10.	Elkayam U, Janmohamed M, Habib M and Hatamizadeh P: Vasodilators in the management of acute heart failure. Crit Care Med. 36(Suppl 1): S95–S105. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Hollenberg SM: Vasodilators in acute heart failure. Heart Fail Rev. 12:143–147. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Metra M, Teerlink JR, Voors AA, Felker GM, Milo-Cotter O, Weatherley B, Dittrich H and Cotter G: Vasodilators in the treatment of acute heart failure: What we know, what we don't. Heart Fail Rev. 14:299–307. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S and Derakhshani M: Intravenous nitroglycerin in the treatment of decompensated heart failure: Potential benefits and limitations. J Cardiovasc Pharmacol Ther. 9:227–241. 2004. View Article : Google Scholar : PubMed/NCBI
14.	den Uil CA and Brugts JJ: Impact of intravenous nitroglycerin in the management of acute decompensated heart failure. Curr Heart Fail Rep. 12:87–93. 2015. View Article : Google Scholar : PubMed/NCBI
15.	Buch J: Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther. 27:426–443. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Tebbe U, Wurst W and Neuhaus KL: Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure. Eur J Clin Pharmacol. 35:305–308. 1988. View Article : Google Scholar : PubMed/NCBI
17.	Yang W, Zhou YJ, Fu Y, Qin J, Qin S, Chen XM, Guo JC and Hua Q: A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly. Am J Med Sci. 350:109–115. 2015. View Article : Google Scholar : PubMed/NCBI
18.	Liu LS: Writing Group of 2010 Chinese Guidelines for the Management of Hypertension: 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 39:579–615. 2011.(In Chinese). PubMed/NCBI
19.	Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL and Johnson MR: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 62:e147–239. 2013. View Article : Google Scholar : PubMed/NCBI
20.	Cherney D and Straus S: Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 17:937–945. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Zink M, Gombotz H, Wasler A, Grasser B, Rehak P and Metzler H: Urapidil reduces elevated pulmonary vascular resistance in patients before heart transplantation. J Heart Lung Transplant. 21:347–353. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Drobinski G, Montalescot G, Fossier JM and Grosgogeat Y: Effects of urapidil by intravenous injection on pulmonary circulation and cardiac function in left ventricular failure. Ann Cardiol Angeiol (Paris). 42:167–172. 1993.PubMed/NCBI
23.	Carlson MD and Eckman PM: Review of vasodilators in acute decompensated heart failure: The old and the new. J Card Fail. 19:478–493. 2013. View Article : Google Scholar : PubMed/NCBI
24.	Fermann GJ and Collins SP: Initial management of patients with acute heart failure. Heart Fail Clin. 9:291–301. 2013. View Article : Google Scholar : PubMed/NCBI
25.	Carlyle PF and Cohn JN: Systemic and regional hemodynamic effects of alpha-adrenoceptor blockade in chronic left ventricular dysfunction in the conscious dog. Am Heart J. 120:619–624. 1990. View Article : Google Scholar : PubMed/NCBI
26.	Wang RY, Chow JS, Chan KH, Pan HY and Wong RP: Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure. Eur Heart J. 5:745–751. 1984.PubMed/NCBI
27.	M'Buyamba-Kabangu JR, Bielen E, Staessen J, Fagard R, Lijnen P, Van Hoof R and Amery A: Hemodynamic effects of urapidil in men. Presse Med. 19:1407–1411. 1990.PubMed/NCBI
28.	Toma M, Ezekowitz JA, Bakal JA, O'Connor CM, Hernandez AF, Sardar MR, Zolty R, Massie BM, Swedberg K and Armstrong PW: The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: Insights from the ASCEND-HF Trial. Eur J Heart Fail. 16:334–341. 2014. View Article : Google Scholar : PubMed/NCBI
29.	Bhardwaj A and Januzzi JL Jr: Natriuretic peptide-guided management of acutely destabilized heart failure: Rationale and treatment algorithm. Crit Pathw Cardiol. 8:146–150. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Parissis JT, Nikolaou M, Mebazaa A, Ikonomidis I, Delgado J, Vilas-Boas F, Paraskevaidis I, McLean A, Kremastinos D and Follath F: Acute pulmonary oedema: Clinical characteristics, prognostic factors and in-hospital management. Eur J Heart Fail. 12:1193–1202. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Kozàkovà M, Marco J, Heusch G, Bernies M, Bossi IM, Palombo C, Anguissola GB, Donatelli F, Laurent JP and Gregorini L: The alpha1-adrenergic blocker urapidil improves contractile function in patients 3 months after coronary stenting: A randomized, double-blinded study. Am Heart J. 147:E62004. View Article : Google Scholar : PubMed/NCBI
32.	Yao DK, Jia SQ, Wang L, Li HW, Zhang YC, Wang YL and Wang LX: Therapeutic effect of urapidil on myocardial perfusion in patients with ST-elevation acute coronary syndrome. Eur J Intern Med. 20:152–157. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Oren S, Turkot S, Paran E, Flandra O, Slezak L and Hof B: Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens. 10:123–127. 1996.PubMed/NCBI